CD276 and posterior cortical atrophy: As in Supplementary Table S2, several ongoing trials evaluating B7-H3-targeted ADCs for PCa (NCT04145622, NCT03729596, and NCT05551117) were designed to rigorously test the efficacy and safety of ADCs.